Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Haemonetics (HAE) Gross Profit (2016 - 2025)

Haemonetics (HAE) has 17 years of Gross Profit data on record, last reported at $202.4 million in Q4 2025.

  • For Q4 2025, Gross Profit rose 4.57% year-over-year to $202.4 million; the TTM value through Dec 2025 reached $782.4 million, up 6.92%, while the annual FY2025 figure was $749.0 million, 8.3% up from the prior year.
  • Gross Profit reached $202.4 million in Q4 2025 per HAE's latest filing, up from $194.7 million in the prior quarter.
  • Across five years, Gross Profit topped out at $202.4 million in Q4 2025 and bottomed at $81.8 million in Q2 2021.
  • Average Gross Profit over 5 years is $161.6 million, with a median of $168.9 million recorded in 2023.
  • Peak YoY movement for Gross Profit: dropped 27.96% in 2021, then soared 66.63% in 2022.
  • A 5-year view of Gross Profit shows it stood at $122.5 million in 2021, then rose by 29.51% to $158.7 million in 2022, then rose by 12.07% to $177.9 million in 2023, then rose by 8.82% to $193.5 million in 2024, then increased by 4.57% to $202.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for Gross Profit were $202.4 million in Q4 2025, $194.7 million in Q3 2025, and $192.2 million in Q2 2025.